Inhibition of modulation of thymus-leukemia antigens by concanavalin A. 1979

C B Wilson, and J R Little

UI MeSH Term Description Entries
D007152 Immunologic Capping An energy dependent process following the crosslinking of B CELL ANTIGEN RECEPTORS by multivalent ligands (bivalent anti-antibodies, LECTINS or ANTIGENS), on the B-cell surface. The crosslinked ligand-antigen receptor complexes collect in patches which flow to and aggregate at one pole of the cell to form a large mass - the cap. The caps may then be endocytosed or shed into the environment. Capping, Immunologic,Immunological Capping,Capping, Immunological
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008297 Male Males
D008560 Membrane Fluidity The motion of phospholipid molecules within the lipid bilayer, dependent on the classes of phospholipids present, their fatty acid composition and degree of unsaturation of the acyl chains, the cholesterol concentration, and temperature. Bilayer Fluidity,Bilayer Fluidities,Fluidities, Bilayer,Fluidities, Membrane,Fluidity, Bilayer,Fluidity, Membrane,Membrane Fluidities
D011952 Receptors, Concanavalin A Glycoprotein moieties on the surfaces of cell membranes that bind concanavalin A selectively; the number and location of the sites depends on the type and condition of the cell. Concanavalin A Binding Sites,Concanavalin A Receptors,Concanavalin A Receptor,Receptor, Concanavalin A
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D003078 Colchicine A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Colchicine, (+-)-Isomer,Colchicine, (R)-Isomer
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females

Related Publications

C B Wilson, and J R Little
July 1968, Journal of immunology (Baltimore, Md. : 1950),
C B Wilson, and J R Little
April 1980, Journal of the National Cancer Institute,
C B Wilson, and J R Little
June 1979, Journal of the National Cancer Institute,
C B Wilson, and J R Little
November 1975, Biochemistry,
C B Wilson, and J R Little
January 1984, Progress in clinical and biological research,
C B Wilson, and J R Little
September 1976, Journal of immunology (Baltimore, Md. : 1950),
C B Wilson, and J R Little
May 1979, Journal of immunology (Baltimore, Md. : 1950),
C B Wilson, and J R Little
August 1980, Journal of immunology (Baltimore, Md. : 1950),
C B Wilson, and J R Little
October 1980, Journal of the National Cancer Institute,
Copied contents to your clipboard!